Skip to main content

Table 4 Therapeutic effect of immune checkpoint inhibitors

From: Programmed cell death ligand 1 measurement study in granulocyte colony-stimulating factor-producing lung cancer: an observational study

Patient characteristics

  

N=8

N

(%)

1st line

6

 

Pembrolizumab

6

100

2nd line

2

 

Nivolumab

2

100

Pembrolizumab

 PR

2

33.3

 SD

1

16.7

 PD

3

50

Nivolumab

 PD

2

100

  1. PR partial response, SD stable disease, PD progressive disease
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us